BAY-069 is a potent branched-chain amino acid transaminases 1 (BCAT1) and BCAT2 inhibitor with IC 50 values of 31 nM and 153 nM, respectively. BAY-069 also can be used as a chemical probe. BAY-069 can be used tor research anticancer In Vitro BAY-069 (compound 36a) (70 nM-50 μM; 72 h) inhibits cell proliferation of U-87 and MDA-MB-231. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: U-87 and MDA-MB-231 Concentration: 70 nM-50 μM Incubation Time: 72 h Result: Inhibited cell proliferation of U-87 and MDA-MB-231 with IC 50 s of 358 nM and 874 nM, respectively. In Vivo BAY-069 exhibits high metabolic stability after incubation with human liver microsomes (CL blood = 0.11 L/h/kg) and moderate metabolic stability after incubation with rat hepatocytes (CL blood = 1.8 L/h/kg); shows high permeability through Caco-2 cell monolayers with no hint of efflux . BAY-069 (0.3 mg/kg for i.v.; 0.6 mg/kg for p.o.; single dosage) exhibits a favorable pharmacokinetic profile after i.v. dosing with low blood clearance (CL blood ), moderate volume of distribution at steady state (V ss ), and intermediate terminal half-life (t 1/2 ). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats Dosage: 0.3 mg/kg for i.v.; 0.6 mg/kg for p.o. Administration: i.v. or p.o.; single dosage Result: Pharmacokinetic Parameters of BAY-069 in male Wistar rats . CL blood (L/h/kg) V ss (L/kg) t 1/2 (h), i.v. AUC norm (kg·h/L), i.v. AUC norm (kg·h/L), p.o. F (%), p.o. 0.64 0.25 1.6 2.9 2.5 89 Form:Solid IC50& Target:IC 50 : 31 nM (BCAT1), 153 nM (BCAT2)